Alpha 2.0

» Articles » PMID: 33598499

Low-density Lipoprotein Cholesterol Lowering Therapy for the Secondary Prevention of Atherosclerotic Cardiovascular Disease

Overview

Overview

Journal Glob Cardiol Sci Pract

Specialty Cardiology & Vascular Diseases

Date 2021 Feb 18

PMID 33598499

Citations 2

Authors

Authors

Parth N Patel

Robert P Giugliano

Affiliations

Affiliations

Soon will be listed here.

Abstract

Atherosclerotic cardiovascular disease (ASCVD) is highly prevalent and a major contributor to morbidity and mortality worldwide. Elevated blood cholesterol is a key driver of risk for atherosclerotic events, and patients with established ASCVD comprise a specific high-risk population in which low-density lipoprotein cholesterol (LDL-C) lowering therapy is strongly endorsed by multiple guidelines. An increasing number of medications across several pharmacologic classes are available today in clinical practice. Therefore, guidance on the appropriate use of these interventions is necessary for cost-effective solutions to managing residual atherothrombotic risk. In this review we summarize the key evidence supporting LDL-C lowering as described in the most recent 2018 multi-society Blood Cholesterol Guidelines, and provide a framework for optimizing LDL-C lowering therapy in secondary prevention populations.

Citing Articles

The clinical effectiveness and safety of low/moderate-intensity statins & ezetimibe combination therapy vs. high-intensity statin monotherapy: a systematic review and meta-analysis.

Sydhom P, Al-Quraishi B, El-Shawaf M, Osman M, Naji N, Awwad N BMC Cardiovasc Disord. 2024; 24(1):660.

PMID: 39567875 PMC: 11577940. DOI: 10.1186/s12872-024-04144-y.

Statins for Patients Undergoing Thoracic Aortic Aneurysm Repair Surgery: What to Do?.

Klein K, Jovin I Aorta (Stamford). 2021; 9(4):169-170.

PMID: 34861741 PMC: 8642068. DOI: 10.1055/s-0041-1736589.

References

1.

Hemphill L . Familial hypercholesterolemia: current treatment options and patient selection for low-density lipoprotein apheresis. J Clin Lipidol. 2010; 4(5):346-9. DOI: 10.1016/j.jacl.2010.08.013. View

2.

Sabatine M, Giugliano R, Keech A, Honarpour N, Wiviott S, Murphy S . Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017; 376(18):1713-1722. DOI: 10.1056/NEJMoa1615664. View

3.

Ballantyne C, McKenney J, MacDougall D, Margulies J, Robinson P, Hanselman J . Effect of ETC-1002 on Serum Low-Density Lipoprotein Cholesterol in Hypercholesterolemic Patients Receiving Statin Therapy. Am J Cardiol. 2016; 117(12):1928-33. DOI: 10.1016/j.amjcard.2016.03.043. View

4.

Moriarty P, Parhofer K, Babirak S, Cornier M, Duell P, Hohenstein B . Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial. Eur Heart J. 2016; 37(48):3588-3595. PMC: 5233802. DOI: 10.1093/eurheartj/ehw388. View

5.

Berglund L, Brunzell J, Goldberg A, Goldberg I, Sacks F, Murad M . Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012; 97(9):2969-89. PMC: 3431581. DOI: 10.1210/jc.2011-3213. View

6.

Landray M, Haynes R, Hopewell J, Parish S, Aung T, Tomson J . Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014; 371(3):203-12. DOI: 10.1056/NEJMoa1300955. View

7.

Ray K, Wright R, Kallend D, Koenig W, Leiter L, Raal F . Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med. 2020; 382(16):1507-1519. DOI: 10.1056/NEJMoa1912387. View

8.

Ford E, Ajani U, Croft J, Critchley J, Labarthe D, Kottke T . Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med. 2007; 356(23):2388-98. DOI: 10.1056/NEJMsa053935. View

9.

Gencer B, Marston N, Im K, Cannon C, Sever P, Keech A . Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. Lancet. 2020; 396(10263):1637-1643. PMC: 8015314. DOI: 10.1016/S0140-6736(20)32332-1. View

10.

Giugliano R, Keech A, Murphy S, Huber K, Tokgozoglu S, Lewis B . Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial. JAMA Cardiol. 2017; 2(12):1385-1391. PMC: 5815002. DOI: 10.1001/jamacardio.2017.3944. View

11.

Huijgen R, Abbink E, Bruckert E, Stalenhoef A, Imholz B, Durrington P . Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week, multicenter, randomized, double-blind, controlled trial. Clin Ther. 2010; 32(4):615-25. DOI: 10.1016/j.clinthera.2010.04.014. View

12.

Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S . Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation. 2006; 115(4):450-8. DOI: 10.1161/CIRCULATIONAHA.106.637793. View

13.

Roth G, Johnson C, Abajobir A, Abd-Allah F, Abera S, Abyu G . Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015. J Am Coll Cardiol. 2017; 70(1):1-25. PMC: 5491406. DOI: 10.1016/j.jacc.2017.04.052. View

14.

Ference B . Mendelian randomization studies: using naturally randomized genetic data to fill evidence gaps. Curr Opin Lipidol. 2016; 26(6):566-71. DOI: 10.1097/MOL.0000000000000247. View

15.

Di Angelantonio E, Gao P, Pennells L, Kaptoge S, Caslake M, Thompson A . Lipid-related markers and cardiovascular disease prediction. JAMA. 2012; 307(23):2499-506. PMC: 4211641. DOI: 10.1001/jama.2012.6571. View

16.

Mabuchi H, Koizumi J, Shimizu M, Kajinami K, Miyamoto S, Ueda K . Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group. Am J Cardiol. 1999; 82(12):1489-95. DOI: 10.1016/s0002-9149(98)00692-4. View

17.

Nauck M, Warnick G, Rifai N . Methods for measurement of LDL-cholesterol: a critical assessment of direct measurement by homogeneous assays versus calculation. Clin Chem. 2002; 48(2):236-54. View

18.

Bergeron N, P Phan B, Ding Y, Fong A, Krauss R . Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk. Circulation. 2015; 132(17):1648-66. DOI: 10.1161/CIRCULATIONAHA.115.016080. View

19.

Ross S, DMello M, Anand S, Eikelboom J, Stewart A, Samani N . Effect of Bile Acid Sequestrants on the Risk of Cardiovascular Events: A Mendelian Randomization Analysis. Circ Cardiovasc Genet. 2015; 8(4):618-27. DOI: 10.1161/CIRCGENETICS.114.000952. View

20.

Nicholls S, Brandrup-Wognsen G, Palmer M, Barter P . Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am J Cardiol. 2010; 105(1):69-76. DOI: 10.1016/j.amjcard.2009.08.651. View